For the year ending 2025-12-31, MBRX had $4,600K increase in cash & cash equivalents over the period. -$22,735K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -33,560 |
| Depreciation and amortization | 90 |
| Stock-based compensation | 1,664 |
| Change in fair value of warrant liabilities | -24,441 |
| Loss on issuance of warrant liabilities | -30,962 |
| Transaction costs allocated to warrant liabilities | 1,407 |
| Loss on extinguishment of warrant liabilities | -614 |
| Operating lease, net | -26 |
| Prepaid expenses and other assets | 792 |
| Accounts payable | 1,330 |
| Accrued expenses and other liabilities | 17 |
| Net cash used in operating activities | -22,735 |
| Purchase of fixed assets | 0 |
| Net cash used in investing activities | 0 |
| Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs | 25,765 |
| Proceeds from exercise of warrants | 1,527 |
| Payment of tax liability for vested restricted stock units | 8 |
| Net cash provided by financing activities | 27,284 |
| Effect of exchange rate changes on cash and cash equivalents | 51 |
| Net increase (decrease) in cash and cash equivalents | 4,600 |
| Cash and cash equivalents, at beginning of year | 4,278 |
| Cash and cash equivalents, at end of year | 8,878 |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)